← Back to Search

Dietary Supplement

RGMA001 for Non-alcoholic Fatty Liver Disease

N/A
Waitlist Available
Led By John Poulos, MD
Research Sponsored by Biovil Research Group, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male and female patients age 18 years and older.
A clinical or histologic or radiographic diagnosis of NAFLD.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 weeks
Awards & highlights

Study Summary

A research study of a compound containing vitamin E, silymarin and carnitine, three over the counter supplements. The investigators hope to learn if the new supplement can safely and successfully treat fatty liver disease or Non Alcoholic Fatty Liver Disease (NAFLD).

Eligible Conditions
  • Non-alcoholic Fatty Liver Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy
Secondary outcome measures
Safety

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: RGMA001Active Control1 Intervention
Proprietary blend of Vitamin E, Silymarin, and Carnitine.
Group II: Sugar PillPlacebo Group1 Intervention
No treatment.

Find a Location

Who is running the clinical trial?

Biovil Research Group, LLCLead Sponsor
John Poulos, MDPrincipal InvestigatorCumberland Research Associates

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Mar 2025